EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Impact of vitamin D supplementation and status on seizure frequency and quality of life in drug‐resistant epilepsy: A systematic review and meta‐analysis

Bassel Alrabadi, Hasan I. Matar, Natalie Bandak, Yamen Refai, Fadi Alrabadi, Omar Alomari

Epileptic Disorders · 2026-10 · 28 (5) · 1431-1443

DOI: 10.1002/epd2.70294 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and is associated with significant morbidity and reduced quality of life. Emerging evidence suggests that vitamin D may influence neuronal excitability and neuroinflammatory pathways, potentially impacting seizure control. Objective To systematically evaluate the effect of vitamin D supplementation and baseline vitamin D status on seizure frequency, biochemical outcomes, and quality of life in patients with drug‐resistant epilepsy. Methods PubMed, Scopus, and Web of Science were searched from inception through March 2026. Eligible studies assessed vitamin D supplementation or serum vitamin D levels in DRE patients. Results Eleven studies were included, with four studies ( n = 183) contributing to the meta‐analysis of supplementation outcomes. Vitamin D supplementation was associated with a significant reduction in seizure frequency (mean difference [MD] = −8.31 seizures/month, 95% CI [−13.38, −3.25], p = .001) and a significant increase in serum vitamin D levels (MD = 18.4 nmol/L, 95% CI [4.26, 32.54], p = .01). No significant difference in baseline vitamin D levels was observed between drug‐resistant and drug‐responsive epilepsy (MD = .79 nmol/L, 95% CI [−.31, 1.89], p = .16). Qualitative findings suggested potential improvements in quality of life and fatigue with long‐term supplementation, although short‐term effects and neuroinflammatory marker changes were inconsistent. Conclusion Vitamin D supplementation is a safe adjunctive therapy that may reduce seizure frequency in drug‐resistant epilepsy, though further large‐scale trials are needed to confirm its efficacy and define optimal use.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →